1 unknown, 1 withdrawn. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Li Junmin: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) Decitabine, Arsenic Trioxide - Myelodysplastic Syndromes, P53 Mutation | Phase 3 | Withdrawn | Li Junmin | 2018-03-20 | 2023-08-16 | |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations Decitabine, Arsenic Trioxide, Cytarabine - Acute Myeloid Leukemia, P53 Mutation | Phase 2 | Unknown | Li Junmin | 100 | 2018-03-01 | 2018-01-04 |
Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Arsenic (2) · Arsenic Trioxide (2) · Decitabine (2) · Cytarabine (1)
China (2)
Lu Min (2) · Zhang Sujiang (2)